During 2019, Premark successfully completed seed financing rounds, which generated sufficient funds to maintain business activities up to the commencement of the planned PMP2207 Phase 3 programme in blepharitis.
The lead investor is a consortium of predominantly US-based ophthalmologists. The group is represented on the Board of Directors by William Stewart, himself an ophthalmologist, with considerable experience in supporting start-ups in the ophthalmology space.
Premark is now seeking additional financial support for the planned Phase III programme. We would be delighted to hear from prospective investors.
Please contact us for more information.